Related Experiment Videos
Diagnosis of familial hypercholesterolaemia using DNA probes for the low-density lipoprotein (LDL) receptor gene
A E Armston1, S A Iversen, J F Burke
1Department of Chemical Pathology, Royal Sussex County Hospital, Brighton, UK.
Insights
Diagnosing familial hypercholesterolaemia (FH) using recombinant DNA technology shows limited value. Current methods using LDL-receptor probes are only informative in a small percentage of families studied.
Area of Science:
- Genetics
- Molecular Biology
- Cardiovascular Disease
Background:
- Familial hypercholesterolaemia (FH) is a common inherited disorder.
- It leads to elevated LDL cholesterol and premature heart disease.
- Accurate diagnosis is crucial for patient management.
Purpose of the Study:
- To evaluate recombinant DNA technology for diagnosing FH.
- To assess the utility of LDL-receptor cDNA probes in FH diagnosis.
Main Methods:
- Utilized cDNA probes targeting the LDL-receptor gene.
- Investigated restriction fragment length polymorphisms (RFLPs).
- Assessed the informativeness of probes in FH families.
Main Results:
- A 3' LDL-receptor probe was informative in 20% of families.
- A 5' LDL-receptor probe could directly detect mutations in 6% of families.
- Current recombinant DNA technology offers limited diagnostic value for FH.
Conclusions:
- Recombinant DNA technology has limited utility for FH diagnosis currently.
- Further research is needed to develop more informative RFLPs or oligonucleotide probes.
- Improved diagnostic tools are essential for effective FH management.
Abstract:
Familial hypercholesterolaemia (FH) is one of the most commonly inherited diseases. It is characterised by an abnormal LDL receptor resulting in a selective elevation of serum LDL and cholesterol levels. The correlation between FH and premature heart disease means that these patients contribute significantly to the number of individuals presenting with coronary heart disease. In the work described here cDNA probes to LDL-receptor were used to assess the usefulness of recombinant DNA technology to diagnose familial hypercholesterolaemia. A 3' probe to the LDL-receptor which detects a restriction fragment length polymorphism (RFLP) in linkage disequilibrium with normal and mutant LDL-receptor genes, was found to be potentially informative in 20% of the families studied. In addition a 5' probe to the LDL-receptor may be capable of directly detecting mutations in some 6% of families. We suggest that until further work has established other RFLP's or oligonucleotide probes are synthesised to directly detect mutant LDL-receptor genes, recombinant DNA technology is only of limited value for diagnosing familial hypercholesterolaemia.